Nanofilament-directed Immunotherapy Shows Promising Results in Treating Solid Tumors
TATUM bioscience, a preclinical biotechnology company developing a new immunotherapy to fight cancer, announced the publication of new research showing strong antitumor activity from its proprietary bioengineered multimodal nanofilaments. The study, published in the new issue of the Journal for Immunotherapy of Cancer (JITC), details how this groundbreaking therapy exposes (“uncloaks”) cancer cells and orchestrates a comprehensive immune response that eradicates tumors.
